Research Article
The Prognostic Utility of Plasma NGAL Levels in ST Segment Elevation in Myocardial Infarction Patients
Table 1
Clinical and biochemical characteristics in patients with STEMI.
| | n = 68 |
| Female sex, n (%) | 12 (17.6) | Age, years | 61.51 ± 14.72 | DM, n (%) | 12 (17.6) | HT, n (%) | 29 (42.6) | DL, n (%) | 8 (11.8) | Smoking, n (%) | 51 (75) | Family history of CAD, n (%) | 9 (13.4) | Admission time (hours) | 4.61 ± 2.96 | Admission SBP (mmHg) | 114.93 ± 22.58 | Anterior wall MI, n (%) | 25 (36.8) | Inferior wall MI, n (%) | 33 (48.5) | Posterolateral wall MI, n (%) | 10 (14.7) | Primer PCI, n (%) | 40 (58.8) | Fibrinolytic administration, n (%) | 30 (44.1) | NGAL (ng/ml) | 190.08 (9.00–694.00) | Troponin I (ng/ml) | 1.51 (0.10–25.00) | CKMB (ng/ml) | 14.99 (1.63–380.00) | CRP (mg/dl) | 0.53 (0.05–9.59) | Creatinine (mg/dl) | 0.88 ± 0.19 | GFR (ml/min) | 101.47 ± 23.29 | LDL (mg/dl) | 124.35 ± 34.70 | HDL (mg/dl) | 36.65 ± 9.04 | Haemoglobin (mg/dl) | 14.83 ± 2.27 | Leukocytes (K/uL) | 12.27 ± 0.45 | Platelets (K/uL) | 240 (72–485) | Neutrophils (K/uL) | 8.99 ± 4.07 | Lymphocytes (K/uL) | 2.21 ± 1.39 |
|
|